Halozyme Therapeutics Inc (HALO) — closed signal from May 5, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 3, 2026.
Predicted vs. what happened
HALO price · publication thesis → realized outcomesplit-adjusted
$62.50 – $65.50Entry zone — fair-value band
$64.70Published — price the day we called it
$77.64Target — the price the thesis aimed for
$84.44Peak — highest point inside the window, not a realized return
$82.27Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 56 days.
Peak price
$84.44
peak on July 28, 2026 — not a realized returnPeak gain
+30.5%
peak, from the publication priceWindow close
$82.27
end-of-window price, context onlyDays to target
56
Window
May 5, 2026 – August 3, 2026
The thesis — published May 5, 2026
Predicted growth
+20%
over the measurement windowTarget price
$77.64
the price the thesis aimed forEntry zone
$62.50 – $65.50
the fair-value band we waited forPrice at publication
$64.70
published May 5, 2026Confidence
68%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Halozyme earns from partnerships and royalties and recent announcements support the idea royalties will keep growing. A new CFO from a large drug company adds credibility. Near-term quarterly results give a chance for good news, but company debt and insider stock selling make the short-term outlook cautious rather than strongly bullish.
Primary drivers
- Growing royalty income from partner drug sales is a core revenue source
- Experienced CFO improves confidence in execution and finances
- Quarterly results are a near-term event that could move the story
- Partnering platform creates repeatable revenue opportunities over time
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.